Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
FCBC$47.50+0.05(+0.11%)First Community Bankshares, Inc. Announces Acquisition of Main Street Financial Services Corp.[8:17:00 AM ET]BEN$31.39+0.40(+1.29%)ChinaAMC and Franklin Templeton Sign Strategic MOU to Deepen Cross-Border Collaboration China Asset Management Co., Ltd. (ChinaAMC) and Franklin Templeton today announced in Shenzhen, China, the signing of a strategic Memorandum of...[8:17:00 AM ET]AGCO$103.40-0.81(-0.78%)AGCO Names Georgia Educator Ben Brand Inaugural Ag Mechanics Teacher of the Year AGCO (NYSE: AGCO) named Ben Brand of Social Circle High School in Social Circle, Georgia, the inaugural Agricultural Mechanics Teacher of the Year....[8:15:00 AM ET]MDA$29.30+0.03(+0.10%)49North Qualifies Across All Five Streams of Canada's Defence Drone Initiative Marketplace 49North, a wholly owned subsidiary of MDA Space Ltd. (TSX: MDA) (NYSE: MDA), today announced that it has qualified across all five streams of...[8:15:00 AM ET]GREH$0.01+0.00(+2.30%)Green Rain Energy Holdings Highlights Three Completed EV Charging Projects in New York and California, Looks Ahead to Continued Expansion[8:15:00 AM ET]INFY$11.91-0.20(-1.62%)Canada's UNI Financial Cooperation Advances Branch Modernization with Infosys Finacle Universal Banker Infosys Finacle, part of EdgeVerve Systems, a wholly owned subsidiary of Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), and UNI Financial Cooperation...[8:14:00 AM ET]CYMHF$0.07+0.01(+14.90%)KAP MINERALS AND CYMAT TECHNOLOGIES ANNOUNCE STRATEGIC PARTNERSHIP TO DEVELOP CANADIAN SCANDIUM-ALUMINUM MASTER ALLOY PRODUCTION KAP Minerals Inc. ("KAP") and Cymat Technologies Ltd. (TSXV: CYM) (OTCQB: CYMHF) ("Cymat") are pleased to announce the signing of a Memorandum of...[8:10:00 AM ET]GEVO$1.18+0.01(+0.85%)Gevo Announces Appointment of K’Lynne Johnson to Board of Directors[8:10:00 AM ET]MXCT$1.57+0.03(+1.95%)MaxCyte to Participate in Three Upcoming Investor Conferences[8:05:00 AM ET]TDTH$0.58-0.02(-3.62%)Trident Founder & CEO to Buy Up to 1,000,000 Shares in the Open Market[8:05:00 AM ET]MTOPF$0.020.00(0.00%)Barbrook Gold Mine Business Rescue Plan is Advancing - Lions Bay Resources Corrects Misleading Vantage Goldfield Claims[8:04:00 AM ET]AMTX$1.29-0.02(-1.53%)Aemetis to Review Third Quarter 2026 Financial Results on November 5, 2026[8:03:22 AM ET]SATL$4.00+0.05(+1.25%)Satellogic Schedules Third Quarter 2026 Results Conference Call on Tuesday, November 10, 2026, at 4:30 p.m. Eastern Time[8:00:00 AM ET]BA$168.48+0.30(+0.18%)Boeing: Global Freighter Fleet to Exceed 4,000 Airplanes as Air Cargo Traffic Doubles by 2045 Boeing [NYSE: BA] projects in its 2026 World Air Cargo Forecast that air cargo traffic will double over the next 20 years, driving the freighter...[8:00:00 AM ET]BCAL$21.59-0.36(-1.64%)CALIFORNIA BANCORP REPORTS THIRD QUARTER EARNINGS, HIGHLIGHTED BY STEADY LOAN GROWTH AND STRONG DEPOSIT GROWTH[8:00:00 AM ET]

MLYS · NASDAQ

Mineralys Therapeutics, Inc.

$22.25 +1.11 (+5.23%)

Company overview

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. Its clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$2B
Employees
51
Headquarters
Radnor, PA
Website
mineralystx.com
CEO
Jon Congleton
Listed
February 10, 2023
P/E
-10.93
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$21,000
Operating income
-$171M
EBITDA
-$167M
Net income
-$152M
EPS
-$2.05
Total assets
$653M
Total debt
$0.00
Earnings yield
-9.15%

Price chart

19.6422.8826.1329.3832.62
MLYS 1D NASDAQ O20.59H21.23L20.28C21.15+0.59 (+2.85%)Vol908.30K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
MLYSMineralys Therapeutics, Inc. Press release Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International GlobeNewswire
MLYSMineralys Therapeutics, Inc. Press release Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026 GlobeNewswire
MLYSMineralys Therapeutics, Inc. Press release Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats GlobeNewswire
MLYSMineralys Therapeutics, Inc. Stock news Mineralys (NASDAQ: MLYS) CEO sells 75,000 shares under prearranged plan Defense World
MLYSMineralys Therapeutics, Inc. Stock news Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026 GlobeNewsWire
MLYSMineralys Therapeutics, Inc. Press release Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026 GlobeNewsWire
MLYSMineralys Therapeutics, Inc. Press release Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum GlobeNewsWire
MLYSMineralys Therapeutics, Inc. Press release Mineralys Therapeutics' Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026 GlobeNewsWire
MLYSMineralys Therapeutics, Inc. Press release Mineralys Therapeutics Reports Inducement Awards Under GlobeNewswire
MLYSMineralys Therapeutics, Inc. Stock news Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Director Sells $85,740.00 in Stock Defense World
MLYSMineralys Therapeutics, Inc. Press release Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
MLYSMineralys Therapeutics, Inc. Stock news Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision Seeking Alpha
MLYSMineralys Therapeutics, Inc. Stock news BlackRock Inc. Buys New Position in Mineralys Therapeutics, Inc. $MLYS Defense World
MLYSMineralys Therapeutics, Inc. Press release Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference GlobeNewsWire
MLYSMineralys Therapeutics, Inc. Stock news Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript Seeking Alpha
MLYSMineralys Therapeutics, Inc. Stock news Mineralys Therapeutics Q2 Earnings Call Highlights MarketBeat
MLYSMineralys Therapeutics, Inc. Press release Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update GlobeNewsWire
MLYSMineralys Therapeutics, Inc. Press release Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) GlobeNewsWire
MLYSMineralys Therapeutics, Inc. Press release Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference GlobeNewsWire
MLYSMineralys Therapeutics, Inc. Press release Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) GlobeNewsWire
See more
FAQ

Questions about Mineralys Therapeutics, Inc.

What does Mineralys Therapeutics, Inc. do?
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. Its clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
What is MLYS's market cap?
Mineralys Therapeutics, Inc. (MLYS) is a listed stock with a live quote. The latest market cap on this page is $2B.
Where is Mineralys Therapeutics, Inc. headquartered?
Mineralys Therapeutics, Inc. is headquartered in Radnor, PA.
How do I get MLYS news from the API?
Call GET /v1/news?tickers=MLYS. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does MLYS news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for MLYS, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the MLYS price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs